USA News Group News
Commentary
Issued on behalf of Oncolytics Biotech
Inc.
VANCOUVER, BC, Feb. 19,
2025 /PRNewswire/ -- USA News Group News Commentary –
Amid the excitement surrounding Project Stargate—the
$500 billion investment aimed
at revolutionizing AI-driven data centers—concerns over the rising
global cancer rates, particularly among younger populations, remain
pressing. Lifestyle factors are increasingly under scrutiny, with
the World Health Organization (WHO) now advocating for
cancer warning labels on alcohol products. Despite these alarming
trends, several biotech companies have already made notable strides
in 2025, with recent advancements coming from Oncolytics Biotech
Inc. (NASDAQ: ONCY) (TSX: ONC), GRAIL, Inc. (NASDAQ:
GRAL), Quest Diagnostics Incorporated (NYSE: DGX),
Renovaro Inc. (NASDAQ: RENB), and Predictive Oncology
Inc. (NASDAQ: POAI).
The article continued: The Center for Innovation and
Translation of Point of Care Technologies for Equitable Cancer Care
(CITEC) has launched a global initiative focused on
accelerating next-generation cancer detection technologies. With
demand for advanced oncology solutions increasing, industry
projections suggest significant market expansion, as
DelveInsight Business Research forecasts a 9.12% compound
annual growth rate (CAGR)—pushing the global cancer therapy market
to an estimated $285.96 billion by
2030.
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key
Pancreatic and Anal Cancer Advances in Addition to Metastatic
Breast Cancer
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a
clinical-stage company focused on immunotherapy for
cancer, continues to make good progress in 2025 with key
regulatory and clinical advancements, reinforcing pelareorep's
potential in hard-to-treat cancers. Oncolytics was pleased
to highlight two significant developments for its immunotherapy,
pelareorep: the safety and regulatory clearance to advance
enrollment in its pancreatic cancer study and the recent
presentation of new efficacy and safety data at the 2025
American Society of Clinical Oncology (ASCO)
Gastrointestinal Cancers Symposium in late January.
"We're hitting critical milestones that validate our progress
and set the stage for what we believe will be an exciting year,"
said Wayne Pisano, Interim CEO and
Chair of Oncolytics' Board of Directors. "With positive feedback
from regulators in place, we're advancing our pancreatic cancer
study toward full enrollment, and our ASCO GI presentations
highlighted pelareorep's strong safety and efficacy results in two
hard-to-treat cancers. We remain focused on bringing new treatment
options to patients while creating value for shareholders as we
move forward in 2025."
Germany's
Paul-Ehrlich-Institute (PEI) has granted Oncolytics Biotech
approval to proceed with full enrollment in its pancreatic cancer
trial (GOBLET Cohort 5) following a successful safety review. This
milestone allows the study to advance as planned, with 30 patients
set to participate in Stage 1 across two treatment arms evaluating
pelareorep in combination with modified FOLFIRINOX, with or without
atezolizumab. With the safety run-in complete, Oncolytics
will continue gathering safety data, with an initial efficacy
readout expected later this year. This progress reinforces
pelareorep's potential in one of the most aggressive and
challenging-to-treat cancers, bringing the company one step closer
to expanding its clinical impact in gastrointestinal oncology.
At ASCO GI 2025, Oncolytics Biotech presented new
clinical data reinforcing pelareorep's potential in two
difficult-to-treat cancers: anal and pancreatic cancer. In anal
cancer, patients receiving pelareorep + atezolizumab continue to
show stronger-than-expected responses, outperforming results seen
in published studies using checkpoint inhibitors alone. In
pancreatic cancer, pelareorep has previously demonstrated a strong
efficacy signal in combination with gemcitabine, nab-paclitaxel,
and atezolizumab. The latest findings confirm a favorable safety
profile when using pelareorep with a different chemotherapy regimen
(modified FOLFIRINOX), with and without atezolizumab, potentially
broadening its clinical applications. These results further de-risk
pelareorep's development and could support the advancement into
larger, registration-enabling trials, bringing the therapy closer
to addressing major unmet needs in gastrointestinal oncology.
As Oncolytics moves into a pivotal year, multiple
high-impact milestones are set to shape the company's progress.
Upcoming data readouts from ongoing gastrointestinal cancer trials
will provide further insights, including translational results that
help characterize pelareorep's mechanism of action. Additionally,
regulatory interactions throughout the year could play a crucial
role in accelerating future trials, bringing pelareorep closer to
potential registration-enabling studies in both breast and
gastrointestinal cancers. These milestones position
Oncolytics for continued momentum as it advances its
clinical pipeline toward broader patient impact.
"We're seeing clinical validation across multiple studies,"
added Pisano. "With encouraging regulatory interactions in hand and
data readouts ahead, 2025 is shaping up to be an exciting year for
Oncolytics and our investors. As we have shown in GOBLET,
BRACELET-1, and numerous previous studies, pelareorep has a
favorable safety profile and efficacy signals across multiple
indications with a high unmet need. We are excited about the
potential for moving to a registration-enabling study in breast
cancer and advancing our clinical program in gastrointestinal
cancers."
CONTINUED… Read this and more news for Oncolytics Biotech
at:
https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/
In other recent industry developments and happenings in the
market include:
GRAIL, Inc. (NASDAQ: GRAL), a healthcare company
whose mission is to detect cancer early when it can be cured, and
Quest Diagnostics Incorporated (NYSE: DGX), a leading
provider of diagnostic information services, recently announced the
initial phase of a program to improve provider access to
GRAIL's Galleri® multi-cancer early
detection (MCED) test.
Providers can now order the Galleri test directly from
GRAIL through the Quest Diagnostics connectivity
system. The Quest Diagnostics connectivity system enables
providers in the United States to order and receive
reports of laboratory tests electronically through Quest's
Quanum laboratory portal and more than 900 electronic health record
(EHR) systems. More than 500,000 providers used the Quest
connectivity system last year.
"Quest Diagnostics and GRAIL share a commitment to
improving access to cancer screening and have worked productively
together to enable patient access to GRAIL's Galleri test
via Quest's phlebotomy network since 2021," said Mark
Gardner, Senior Vice President, Molecular Genomics and Oncology for
Quest Diagnostics. "Integrating GRAIL's Galleri test
into the Quest connectivity system is the next step in this
collaboration. We expect it to increase patient access by giving
Quest's provider clients the ability to seamlessly order the
test through Quest, same as they do for other blood work.
This collaboration brings to life the tremendous value of
Quest's ability to scale diagnostic innovation to make it
accessible for all."
Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer
diagnostics and therapeutics powered by artificial intelligence,
recently announced it entered into a binding LOI to acquire
Predictive Oncology Inc. (NASDAQ: POAI) in an all-stock
transaction.
By leveraging Predictive Oncology's extensive biobank of
150,000 tumor samples, Renovaro gains a critical resource to
accelerate biomarker discovery, optimize clinical trials, and
enhance decision-support tools across multiple cancer types. The
combined organization will operate a state-of-the-art, CLIA,
NYSDOH, and CA-certified laboratory staffed by an experienced team,
streamlining diagnostic test development and validation while
expanding market reach in Europe.
Additionally, Renovaro introduces a novel in vivo
chemosensitivity and resistance assay, improving cancer treatment
predictions for European patients and enabling multi-omic
collaborations for drug discovery.
"We recognize that by integrating Predictive Oncology's
AI-driven drug discovery platform and vast biobank of more than
150,000 patient tumor samples, 200,000 pathology slides and decades
of longitudinal drug response data with Renovaro's
multi-disciplinary artificial intelligence, multi-omics and
multi-modal data expertise, we are opening to door to diagnostic,
therapeutic and drug discovery possibilities that we otherwise
would never have considered," said Raymond
Vennare, CEO of Predictive Oncology.
In the long term, this partnership lays the foundation for a
global point-of-care cancer solution, integrating Predictive
Oncology's AI-driven small molecule solid tumor expertise with
Renovaro's AI-powered liquid biopsy and cancer vaccine
programs. This first-in-class, full-stack clinical service has the
potential to advance cancer therapy at every stage—from early
detection and diagnostics to personalized treatment and biomarker
discovery—ultimately improving patient outcomes and reducing
costs.
"Renovaro is on a quest to offer cancer patients early
diagnostic options, treatment protocols, and recurrence
monitoring," said David Weinstein,
CEO of Renovaro. "Predictive Oncology will enhance
our capabilities by assisting oncologists with patient specific
diagnostic and therapeutic clinical support data. Predictive
Oncology's proprietary AI/ML platform has been proven to
predict tumor-drug response with 92% accuracy which, I believe,
will allow us to launch as a decision support platform for medical
oncologists in 2025. As importantly, there are strong synergies
with Predictive's small molecule solid tumor drug-tumor
response modeling capabilities and Renovaro's liquid biopsy
approach to early cancer detection and monitoring."
Source:
https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/
CONTACT:
USA NEWS
GROUP
info@usanewsgroup.com
(604)
265-2873
DISCLAIMER: Nothing in this publication should be
considered as personalized financial advice. We are not licensed
under securities laws to address your particular financial
situation. No communication by our employees to you should be
deemed as personalized financial advice. Please consult a licensed
financial advisor before making any investment decision. This is a
paid advertisement and is neither an offer nor recommendation to
buy or sell any security. We hold no investment licenses and are
thus neither licensed nor qualified to provide investment advice.
The content in this report or email is not provided to any
individual with a view toward their individual circumstances.
USA News Group is a wholly-owned
subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been
paid a fee for Oncolytics Biotech Inc. advertising and digital
media from the company directly. There may be 3rd parties who may
have shares of Oncolytics Biotech Inc., and may liquidate their
shares which could have a negative effect on the price of the
stock. This compensation constitutes a conflict of interest as to
our ability to remain objective in our communication regarding the
profiled company. Because of this conflict, individuals are
strongly encouraged to not use this publication as the basis for
any investment decision. The owner/operator of MIQ own shares of
Oncolytics Biotech Inc. which were purchased in the open market,
and reserve the right to buy and sell, and will buy and sell shares
of Oncolytics Biotech Inc. at any time without any further notice
commencing immediately and ongoing. We also expect further
compensation as an ongoing digital media effort to increase
visibility for the company, no further notice will be given, but
let this disclaimer serve as notice that all material, including
this article, which is disseminated by MIQ has been approved by
Oncolytics Biotech Inc.; this is a paid advertisement, we currently
own shares of Oncolytics Biotech Inc. and will buy and sell shares
of the company in the open market, or through private placements,
and/or other investment vehicles.
While all information is believed to be reliable, it is not
guaranteed by us to be accurate. Individuals should assume that all
information contained in our newsletter is not trustworthy unless
verified by their own independent research. Also, because events
and circumstances frequently do not occur as expected, there will
likely be differences between the any predictions and actual
results. Always consult a licensed investment professional before
making any investment decision. Be extremely careful, investing in
securities carries a high degree of risk; you may likely lose some
or all of the investment.
Logo -
https://mma.prnewswire.com/media/2603685/5175129/USA_News_Group_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/investors-eye-biotech-sector-as-cancer-therapy-market-surges-302380340.html
